Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Amgen logo
AmgenAMGN
$1.48B+50.7%
AbbVie logo
AbbVieABBV
$3.56B+155%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$89.27M-12.1%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s free cash flow?
Oruka Therapeutics, Inc. (ORKA) reported free cash flow of -$23.65M in Q1 2026.
How has Oruka Therapeutics, Inc.'s free cash flow changed year-over-year?
Oruka Therapeutics, Inc.'s free cash flow decreased by 13.3% year-over-year, from -$20.88M to -$23.65M.
What is the long-term trend for Oruka Therapeutics, Inc.'s free cash flow?
Over 3 years (2021 to 2025), Oruka Therapeutics, Inc.'s free cash flow has grown at a 67.5% compound annual growth rate (CAGR), from -$18.81M to -$88.42M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.